Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-0.85
EPS est.
$-1.17
EPS surprise
+27.04%
1-day move
+1.01%
Dianthus Therapeutics reported a narrower loss per share than analysts expected, which contributed to a positive stock reaction, with shares rising 1.01%. However, there was no revenue reported, and no guidance was provided for future performance. Investors may view the EPS beat as a sign of improving financial health, but the lack of revenue and guidance leaves uncertainty about the company's growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | $-1.10 | +27.04% |
| Revenue | $0M | $0M | — |
No transcript is on record, and the analysis is based on numerical results only.
Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs and improve patient outcomes.
Last quarter
In the last quarter, Dianthus reported an EPS of -$1.43, which was worse than expected, leading to a significant stock price increase of 21.52% the following day. This suggests that investors may have reacted positively to other aspects of the report or future potential.
EPS beat streak
2Q
EPS beat rate
50%
Avg EPS surprise
-5.68%
Avg 1-day reaction
+2.80%
Overall, expectations for Dianthus's upcoming earnings are uncertain due to the lack of analyst estimates. Investors are likely looking for any signs of improvement in EPS and revenue growth.
Bull case
If Dianthus can show a smaller loss in EPS than previous quarters, it may indicate progress in its development pipeline, leading to increased investor confidence.
Bear case
Conversely, if the company reports a larger loss or fails to provide any positive updates, it could lead to a significant drop in stock price as investors reassess their outlook.
The print will turn on these.
Q1
What is the expected EPS for this quarter, and how does it compare to previous quarters?
Investors will closely watch EPS as it is a direct measure of the company's profitability and can influence stock performance.
Q2
What updates can management provide regarding revenue growth and product pipeline?
Insights into revenue growth and the status of the product pipeline are crucial for assessing the company's future potential and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be overly focused on short-term EPS losses without considering the potential for long-term growth from Dianthus's product pipeline.
Supporting evidence
The stock has shown resilience with significant price increases following earnings misses, indicating investor optimism.
Options pricing suggests a higher expected move than historical averages, implying that traders anticipate significant developments.
Key risk
If the company provides positive updates on its product pipeline, it could shift sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance will be pivotal in determining whether Dianthus can stabilize its financials and regain investor trust.
Bull confirmed if
A reduction in EPS loss to below -$1.30 would confirm a positive trend and investor confidence.
Bear confirmed if
An EPS loss greater than -$1.50 would reinforce concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±6.79%
Historical Avg
±5.3%
The options market is pricing in a notable move of approximately 6.79%, indicating that traders expect some volatility around the earnings report.
Options are pricing ±6.8% while DNTH has averaged ±5.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
40.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 5 of 18 (28%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 18 (72%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.1%, with a raw directional average of +2.3% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
127.88%
of float
Insider
0.12%
of float
Holders
364
institutions
Top Holders· as of Jun 2026
FMR, LLC
8,199,893 sh · $696.0M
14.96%
5.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Dianthus beats expectations and raises guidance, history suggests a potential stock increase of around 4.51%, confirming a positive outlook.
In line / cautious
If results are in line with expectations but management is cautious, the stock may see minimal movement as investors digest the information.
Miss
If the company misses expectations, history suggests a potential decline of around 4.51%, leading to increased skepticism about future performance.
The lines on the call that would change the story.
Blackrock Inc.
4,123,822 sh · $350.0M
7.53%
29.9%
T. Rowe Price Investment Management, Inc.
3,888,456 sh · $330.1M
7.10%
200.9%
Wellington Management Group, LLP
3,229,882 sh · $274.2M
5.89%
24.4%
Fairmount Funds Management LLC
2,537,191 sh · $215.4M
4.63%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.